Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francisco Jorquera Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodriguez-Abreu, Denis Moro-Sibilot, Christian A. Thomas, Fabrice Barlesi, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yijing Shen, Marcin Kowanetz, Ariel Lopez-Chavez, Alan Sandler, Martin Reck
Institutions: Florida Hospital Cancer Institute, Rocky Mountain Cancer Centers, Azienda Unità Sanitaria Locale Della Romagna, Instituto Nacional del Tórax, Moscow City Oncology Hospital №62, Shikoku Cancer Center, Hospital Universitario Insular de Gran Canaria, Centre Hospitalier Universitaire de Grenoble, New England Cancer Specialists, Hôpital Nord, Allegheny Health Network, Genentech, German Center for Lung Research, LungenClinic Grosshansdorf
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890663189